Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies

High cumulative risks of cancer in patients withPTENhamartoma tumour syndrome

(2013) Virginie Bubien et al.   JOURNAL OF MEDICAL GENETICS

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

(2012) Daniel C. Cho et al.   CANCER

Lifetime Cancer Risks in Individuals with Germline PTEN Mutations

(2012) M.-H. Tan et al.   CLINICAL CANCER RESEARCH

Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity

(2012) Paul G Richardson et al.   Expert Opinion on Drug Metabolism & Toxicology

Autoimmunity, Intestinal Lymphoid Hyperplasia, and Defects in Mucosal B-Cell Homeostasis in Patients With PTEN Hamartoma Tumor Syndrome

(2012) Mario Heindl et al.   GASTROENTEROLOGY

High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

(2011) Paige Yellen et al.   CELL CYCLE

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation

(2011) Ionela Iacobas et al.   PEDIATRIC BLOOD & CANCER

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

PTEN hamartoma tumor syndromes

(2008) Gideon M Blumenthal et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS